Overview
EN ISO 11608-3:2022/A1:2026 specifies updated requirements and test methods for containers and integrated fluid paths in needle-based injection systems (NIS) for medical use. Issued by CEN as an amendment to ISO 11608-3:2022, this standard focuses on the assessment and management of particulate matter within the reservoir and fluid path, with a sustained emphasis on patient safety and product functionality. The document addresses harmonization with relevant pharmacopoeial standards and incorporates a new Annex to clarify particulate requirements and their underlying rationale.
Key Topics
-
Particulate Matter Requirements:
- Updates criteria for both sub-visible and visible particulates in the NIS reservoir and fluid path.
- Sets maximum limits for sub-visible particles per device, referencing ISO 11040-4.
- Calls for risk-based determination of limits adapted to product design and end-use.
-
Visual and Sub-Visual Particulate Limits:
- Sub-visible: Strict numeric limits for particles ≥10 µm and ≥25 µm.
- Visible: Mandates minimization and assessment to ensure particulates do not interfere with device function or patient safety.
-
Design Verification & Risk Assessment:
- Manufacturers must validate particulate controls through design verification, not routine lot release, emphasizing risk assessment tailored to intended use and patient population.
-
Control Strategies:
- Detailed approaches for environmental, supplier, and component controls.
- Periodic re-verification after design changes or process adjustments.
-
Harmonization:
- Cross-references key pharmacopeial and related ISO standards, aligning test methods and specifications for medicinal product safety and compatibility.
Applications
This standard is vital for manufacturers and suppliers of needle-based injection systems, including pen injectors, auto-injectors, and similar drug delivery devices. Key practical applications include:
-
Product Development:
- Ensuring new devices meet up-to-date particulate control and safety benchmarks.
- Supporting risk management throughout the design phase to minimize particulates.
-
Quality Assurance:
- Implementing appropriate test methods for particulate assessment in compliance with international guidelines.
- Creating control programs for manufacturing processes to sustain environmental cleanliness and supplier conformity.
-
Regulatory Compliance:
- Demonstrating adherence to harmonized international standards, which can strengthen submissions to authorities and enable market access.
-
Patient Safety:
- Minimizing risks associated with particulate contamination in injectable therapies, especially for vulnerable patient groups.
This amendment provides essential guidance for both technical and regulatory teams responsible for ensuring the safety and efficacy of injection systems, helping foster reliable medical products and improved patient outcomes.
Related Standards
- ISO 11608 Series: General requirements for needle-based injection systems.
- ISO 11040-4: Prefilled glass syringes-test methods and specifications for sub-visible particulate matter.
- ISO 8536-4: Infusion sets for medical use-requirements for particulate matter.
- USP <788>, <790>, <1790>: US Pharmacopeia test methods and guidelines for particulate matter in injections.
- ICH Q3D, M7: International guidelines addressing elemental and mutagenic impurities in pharmaceuticals.
For manufacturers and stakeholders, familiarity with these related standards supports integrated compliance and robust product development strategies aligned with global best practices in medical device and medicine administration safety.
